| A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study ML Den Boer, M van Slegtenhorst, RX De Menezes, MH Cheok, ... The lancet oncology 10 (2), 125-134, 2009 | 1109 | 2009 |
| A 17-gene stemness score for rapid determination of risk in acute leukaemia SWK Ng, A Mitchell, JA Kennedy, WC Chen, J McLeod, N Ibrahimova, ... Nature 540 (7633), 433-437, 2016 | 778 | 2016 |
| Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment A Holleman, MH Cheok, ML den Boer, W Yang, AJP Veerman, ... New England Journal of Medicine 351 (6), 533-542, 2004 | 731 | 2004 |
| TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) O Kosmider, V Gelsi-Boyer, M Cheok, S Grabar, V Della-Valle, F Picard, ... Blood, The Journal of the American Society of Hematology 114 (15), 3285-3291, 2009 | 356 | 2009 |
| Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy MH Cheok, WE Evans Nature Reviews Cancer 6 (2), 117-129, 2006 | 299 | 2006 |
| Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells MH Cheok, W Yang, CH Pui, JR Downing, C Cheng, CW Naeve, ... Nature genetics 34 (1), 85-90, 2003 | 296 | 2003 |
| Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia G Stocco, MH Cheok, KR Crews, T Dervieux, D French, D Pei, W Yang, ... Clinical Pharmacology & Therapeutics 85 (2), 164-172, 2009 | 269 | 2009 |
| The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia A Holleman, ML den Boer, RX de Menezes, MH Cheok, C Cheng, ... Blood 107 (2), 769-776, 2006 | 198 | 2006 |
| Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia S Lugthart, MH Cheok, ML den Boer, W Yang, A Holleman, C Cheng, ... Cancer cell 7 (4), 375-386, 2005 | 194 | 2005 |
| Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics L Kager, M Cheok, W Yang, G Zaza, Q Cheng, JC Panetta, CH Pui, ... The Journal of clinical investigation 115 (1), 110-117, 2005 | 188 | 2005 |
| Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission O Nibourel, O Kosmider, M Cheok, N Boissel, A Renneville, N Philippe, ... Blood, The Journal of the American Society of Hematology 116 (7), 1132-1135, 2010 | 173 | 2010 |
| Transporter-mediated protection against thiopurine-induced hematopoietic toxicity P Krishnamurthy, M Schwab, K Takenaka, D Nachagari, J Morgan, ... Cancer research 68 (13), 4983-4989, 2008 | 162 | 2008 |
| Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells B Diouf, Q Cheng, NF Krynetskaia, W Yang, M Cheok, D Pei, Y Fan, ... Nature medicine 17 (10), 1298-1303, 2011 | 140 | 2011 |
| A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia AGX Zeng, S Bansal, L Jin, A Mitchell, WC Chen, HA Abbas, ... Nature medicine 28 (6), 1212-1223, 2022 | 133 | 2022 |
| Thiopurine pathway G Zaza, M Cheok, N Krynetskaia, C Thorn, G Stocco, JM Hebert, ... Pharmacogenetics and genomics 20 (9), 573-574, 2010 | 128 | 2010 |
| IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association H Debarri, D Lebon, C Roumier, M Cheok, A Marceau-Renaut, O Nibourel, ... Oncotarget 6 (39), 42345, 2015 | 119 | 2015 |
| In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile MJ Sorich, N Pottier, D Pei, W Yang, L Kager, G Stocco, C Cheng, ... PLoS Medicine 5 (4), e83, 2008 | 97 | 2008 |
| Pharmacogenetics in acute lymphoblastic leukemia MH Cheok, N Pottier, L Kager, WE Evans Seminars in hematology 46 (1), 39-51, 2009 | 93 | 2009 |
| Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion Z Khaznadar, N Boissel, S Agaugué, G Henry, M Cheok, M Vignon, ... The Journal of Immunology 195 (6), 2580-2590, 2015 | 82 | 2015 |
| Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia E Fournier, N Duployez, B Ducourneau, E Raffoux, P Turlure, D Caillot, ... Blood, The Journal of the American Society of Hematology 135 (8), 542-546, 2020 | 73 | 2020 |
